Kristen Kluska

Kristen Kluska Analyst Performance

Managing Director, Biotechnology Equity Research Analyst at Cantor Fitzgerald

Kristen Kluska is a stock analyst at Cantor Fitzgerald focused in the healthcare sector, covering 51 publicly traded companies. Over the past year, Kristen Kluska has issued 44 stock ratings, including strong buy, buy, and hold recommendations. While full access to Kristen Kluska's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Kristen Kluska's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
182 Last 7 Years
Buy Recommendations
84.44% 152 Buy Ratings
Companies Covered
51 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy4.4%8 ratings
Buy80.0%144 ratings
Hold15.6%28 ratings
Sell0.0%0 ratings

Out of 180 total stock ratings issued by Kristen Kluska at Cantor Fitzgerald, the majority (80.0%) have been Buy recommendations, followed by 15.6% Hold and 4.4% Strong Buy.

Exchange Coverage

ExchangePercentageCount
NASDAQ
94.1% of companies on NASDAQ
48 companies
NYSEAMERICAN
3.9% of companies on NYSEAMERICAN
2 companies
NYSE
2.0% of companies on NYSE
1 company

Kristen Kluska, an analyst at Cantor Fitzgerald, currently covers 51 companies listed on NASDAQ, NYSEAMERICAN and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
50 companies
98.0%
Technology
1 company
2.0%

Kristen Kluska of Cantor Fitzgerald specializes in stock coverage within the Healthcare sector, with additional focus on Technology companies.

Coverage Industries

IndustryPercentage
BIOTECHNOLOGY
37 companies
72.5%
PHARMACEUTICALS
11 companies
21.6%
SOFTWARE
1 company
2.0%
LIFE SCIENCES TOOLS & SERVICES
1 company
2.0%
HEALTHCARE EQUIPMENT & SUPPLIES
1 company
2.0%

Kristen Kluska's Ratings History at Cantor Fitzgerald

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
0 Results
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
11/19/2026Reiterated Rating$77.98$170.00Overweight
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
11/13/2026Lower Price Target$9.43$19.00Overweight
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
11/12/2026Reiterated Rating$3.07Overweight
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
11/12/2026Upgrade$70.88$119.00Overweight
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
11/6/2026Boost Price Target$45.71$47.00Neutral
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
11/5/2026Boost Price Target$10.48$13.00Neutral
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
11/4/2026Boost Price Target$28.15$87.00Overweight
KARD
Kardigan
10/29/2026Initiated Coverage$13.73$50.00Overweight
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
10/28/2026Initiated Coverage$1.14$6.00Overweight
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
10/19/2026Boost Price Target$77.25$170.00Overweight
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
9/22/2026Boost Price Target$65.26$137.00Overweight
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
9/22/2026Boost Price Target$33.70$72.00Overweight
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
9/18/2026Boost Price Target$5.59$30.00Overweight
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
9/18/2026Boost Price Target$14.50$39.00Overweight
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
9/3/2026Lower Price Target$26.53$33.00Overweight
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
8/27/2026Boost Price Target$9.72$26.00Overweight
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
8/20/2026Boost Price Target$26.24$103.00Overweight
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
8/14/2026Upgrade$4.21Overweight
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
8/13/2026Downgrade$114.90$119.00Neutral
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
7/30/2026Downgrade$6.67$3.50Neutral
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
7/22/2026Lower Price Target$35.66$61.00Overweight
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
7/16/2026Boost Price Target$78.84$130.00Overweight
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
7/9/2026Boost Price Target$49.35$67.00Overweight
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
6/18/2026Initiated Coverage$12.48$25.00Overweight
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
6/8/2026Boost Price Target$11.23$34.00Overweight
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
5/21/2026Boost Price Target$23.32$96.00Overweight
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
5/19/2026Dropped Coverage$53.01Neutral
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
4/6/2026Downgrade$52.20$53.00Hold
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
3/26/2026Downgrade$9.63Neutral
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
3/13/2026Set Price Target$33.42$62.00Overweight
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
3/9/2026Upgrade$7.35$16.00Overweight
uniQure N.V. stock logo
QURE
uniQure
3/2/2026Downgrade$10.12$9.00Neutral
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
2/20/2026Reiterated Rating$69.49Overweight
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
2/17/2026Lower Price Target$60.55$125.00Overweight
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
1/21/2026Reiterated Rating$71.23Overweight
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
1/15/2026Boost Price Target$8.43$19.00Overweight
uniQure N.V. stock logo
QURE
uniQure
1/14/2026Reiterated Rating$21.50Overweight
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
12/19/2025Downgrade$14.24$14.50Hold
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
12/17/2025Set Price Target$21.74$48.00
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
12/15/2025Upgrade$18.29Strong-Buy
Why I'm selling my Snapback Indicator for just $7 (Ad)

For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel

Get lifetime access to the Snapback Indicator for a one-time $7 payment today.
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
12/14/2025Initiated Coverage$18.37$42.00Overweight
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
12/8/2025Boost Price Target$8.90$24.00Overweight
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
12/1/2025Initiated Coverage$9.83$19.00Overweight
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
11/20/2025Initiated Coverage$9.09$19.00Overweight
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
11/14/2025Reiterated Rating$4.01$13.00Overweight
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
11/6/2025Lower Price Target$9.32$24.00Overweight
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
11/5/2025Boost Price Target$37.75$38.00Neutral
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
10/17/2025Boost Price Target$91.22$153.00Overweight
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
9/30/2025Boost Price Target$47.82$63.00Overweight
uniQure N.V. stock logo
QURE
uniQure
9/25/2025Boost Price Target$47.50$80.00Overweight
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
9/24/2025Reiterated Rating$72.90Overweight
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
9/5/2025Reiterated Rating$31.38$105.00Overweight
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
9/3/2025Reiterated Rating$54.87$118.00Overweight
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
8/27/2025Reiterated Rating$32.03$74.00Overweight
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
8/6/2025Lower Price Target$26.83$105.00Overweight
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
8/6/2025Boost Price Target$41.99$46.00Overweight
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
8/6/2025Boost Price Target$27.64$32.00Neutral
PTC Inc. stock logo
PTC
PTC
7/29/2025Set Price Target$202.95$120.00Overweight
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
7/29/2025Boost Price Target$48.86$120.00Overweight
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
7/24/2025Initiated Coverage$5.14$11.00Overweight
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
7/10/2025Boost Price Target$11.56$29.00Overweight
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
7/7/2025Initiated Coverage$35.87$74.00Overweight
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
6/16/2025Reiterated Rating$19.70Neutral
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
5/22/2025Reiterated Rating$2.88$16.00Overweight
uniQure N.V. stock logo
QURE
uniQure
5/19/2025Upgrade$14.71Strong-Buy
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
5/15/2025Upgrade$5.63$10.00Overweight
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
5/14/2025Reiterated Rating$7.78$25.00Overweight
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
5/14/2025Reiterated Rating$7.77$30.00Overweight
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
5/13/2025Upgrade$2.55Strong-Buy
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
5/7/2025Lower Price Target$38.93$112.00Overweight
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
5/7/2025Boost Price Target$20.51$23.00Neutral
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
5/7/2025Lower Price Target$38.37$81.00Overweight
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
4/28/2025Reiterated Rating$1.86$7.00Overweight
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3/27/2025Boost Price Target$48.97$123.00Overweight
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
3/26/2025Reiterated Rating$7.98$90.00Overweight
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
3/20/2025Reiterated Rating$13.86$30.00Overweight
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
3/18/2025Reiterated Rating$101.35$163.00Overweight
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
3/18/2025Reiterated Rating$2.63$7.00Overweight
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
3/18/2025Boost Price Target$51.27$132.00Overweight
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
3/12/2025Reiterated Rating$7.43$25.00Overweight
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
3/4/2025Reiterated Rating$13.78$25.00Overweight
Mesoblast Limited stock logo
MESO
Mesoblast
3/4/2025Upgrade$14.71Strong-Buy
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
2/26/2025Reiterated Rating$40.80$118.00Overweight
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
2/26/2025Reiterated Rating$32.81$36.00Neutral
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
2/25/2025Upgrade$5.58Strong-Buy
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
2/19/2025Downgrade$39.75$36.00Neutral
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
2/14/2025Initiated Coverage$5.62$23.00Overweight
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
2/3/2025Boost Price Target$49.16$113.00Overweight
Mesoblast Limited stock logo
MESO
Mesoblast
1/30/2025Upgrade$20.14Strong-Buy
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
1/29/2025Reiterated Rating$24.23$67.00Overweight
Drop these 5 stocks before the market opens tomorrow! (Ad)

The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel

See the five stocks Weiss Ratings analysts are watching closely now.
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
1/29/2025Upgrade$7.86Strong-Buy
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
1/22/2025Reiterated Rating$42.28$118.00Overweight
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
1/15/2025Lower Price Target$41.81$76.00Overweight
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
1/15/2025Reiterated Rating$9.21$21.00Overweight
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
1/6/2025Initiated Coverage$36.92$57.00Overweight
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
12/17/2024Initiated Coverage$3.60$17.00Overweight
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
12/17/2024Initiated Coverage$2.33$8.00Overweight
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
12/8/2024Upgrade$3.80Strong-Buy
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
12/2/2024Upgrade$19.57Hold
Codexis, Inc. stock logo
CDXS
Codexis
11/22/2024Reiterated Rating$4.33$11.00Overweight